Invicta Diagnostic share price
NSE: INVICTAHealthcare Services
Invicta Diagnostic Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Dec 2025 · Issue price ₹85
Last close ₹65.00down ₹1.50 (2.26%)
Share price at the NSE close on 28 Oct 2026. Previous close ₹66.50.
28 Oct: open ₹65.00, high ₹65.00, low ₹65.00
Range of traded prices from listing on 8 Dec 2025 to 28 Oct 2026
₹58.10Low, 5 Mar 2026₹105.00High, 8 Dec 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. Market capitalisation: how it is worked out
- ₹82 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 16.66
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.64
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonesince listing in Dec 2025
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record.
- 9.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 12.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.07
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 3,200100.0% delivered
Results
Consolidated; ₹ crore.Invicta Diagnostic half-yearly results
Half year to Mar 2026, against the half year before
- RevenueRevenue. The pill is the change in revenue against the half year before: this period's figure divided by that one's, less one, in per cent.
- ₹15 Crdown 9.09%
- Net profitNet profit. The pill is the change in net profit against the half year before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹0.79 Crdown 80.68%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 5.1%
Revenue by half year
Peak revenue ₹17 Cr, half year to Sep 2025; lowest ₹15 Cr, half year to Mar 2026
Net profit by half year, a loss in red
| ₹ crore | Sep 2025 | Mar 2026 |
|---|---|---|
| Revenue | 16.9 | 15.4 |
| Net profit | 4.1 | 0.8 |
| Net margin | 24.1% | 5.1% |
Consolidated. The 2 half years from Sep 2025, the first on record. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026
- Revenue
- ₹32 Cr
- Net profit
- ₹4.87 Cr
- Net margin
- 15.1%
| ₹ crore | Mar 2026 |
|---|---|
| Revenue | 32.4 |
| Net profit | 4.9 |
| Net margin | 15.1% |
Consolidated. Years to March. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, Diagnostic Services, which carries all its revenue.
Invicta Diagnostic competitors and peers
Healthcare Service Provider, 37 listed companies, priced on 28 Oct 2026. The table lists the 8 companies closest to Invicta Diagnostic in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Choksi LaboratoriesCHOKSILA | 149 | 68.94 | 5.83 | +10.7% | +45.3% | 8.8% | 9.2% | 0.00% |
 Star Imaging and Path LabSTARIMAGIN | 130 | 6.75 | 1.12 | – | – | 16.6% | – | 0.00% |
 Aspira Pathlab & DiagnosticsASPIRA | 129 | – | 10.57 | +14.6% | −117.7% | −3.7% | −4.4% | 0.00% |
 Modern Diagnostic & Research CentreMDRC | 90 | 17.04 | 1.53 | – | – | 9.0% | – | 0.00% |
 Bandaram Pharma PacktechBANDARAM | 35 | – | 1.30 | +133.7% | – | – | 5.6% | 0.00% |
 N.G.IndustriesNGIND | 33 | 17.29 | 0.99 | +2.2% | −74.1% | 5.3% | 3.7% | 3.52% |
 Deccan Health CareDECCAN | 29 | 11.38 | 0.26 | −0.4% | +145.9% | 2.3% | 3.3% | 0.00% |
 Samsrita LabsSAMSRITA | 27 | – | 2.32 | – | – | – | −65.3% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Invicta Diagnostic announcements
Sep 2026
19 Sep · Meeting
17 Sep · Commencement of commercial production/operations
Aug 2026
25 Aug · Board meeting
Invicta Diagnostic share price by year
Each calendar year to 2025.Invicta Diagnostic share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 79.30 | – | 96.70 | 78.30 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2025 is from its first session, 8 Dec 2025.
Recent sessions
The 9 trading days to 27 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 27 Oct 2026 | 63.50 | 66.50 | 63.50 | 66.50 | 65.70 | 6,400 | 100.0% |
| 26 Oct 2026 | 63.00 | 63.00 | 63.00 | 63.00 | 63.00 | 1,600 | 100.0% |
| 23 Oct 2026 | 62.05 | 62.05 | 60.00 | 60.50 | 60.81 | 8,000 | 100.0% |
| 22 Oct 2026 | 64.70 | 64.70 | 64.70 | 64.70 | 64.70 | 3,200 | 100.0% |
| 21 Oct 2026 | 66.00 | 66.00 | 63.15 | 63.15 | 64.40 | 11,200 | 100.0% |
| 15 Oct 2026 | 66.90 | 69.00 | 66.90 | 69.00 | 67.78 | 4,800 | 100.0% |
| 14 Oct 2026 | 64.50 | 67.00 | 64.15 | 67.00 | 65.22 | 4,800 | 66.7% |
| 12 Oct 2026 | 66.30 | 66.30 | 64.50 | 64.50 | 65.40 | 3,200 | 100.0% |
| 9 Oct 2026 | 66.00 | 66.00 | 66.00 | 66.00 | 66.00 | 1,600 | 100.0% |
Prices in ₹ per share as traded, not adjusted.
Company details
- NSE symbol
- INVICTA
- ISIN
- INE0XJ501010
- Industry
- Healthcare Services